<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933721</url>
  </required_header>
  <id_info>
    <org_study_id>BCX7353-312</org_study_id>
    <nct_id>NCT04933721</nct_id>
  </id_info>
  <brief_title>Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies</brief_title>
  <acronym>APeX-A</acronym>
  <official_title>An Open-label Study to Provide Berotralstat Access to Subjects With Type 1 and 2 Hereditary Angioedema Who Were Previously Enrolled in Berotralstat Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3b open-label study providing access to berotralstat for HAE patients who&#xD;
      were previously enrolled in berotralstat studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      APeX-A, 7353-312, is a single-arm, open-label, multicenter study. The study will be conducted&#xD;
      in countries where berotralstat is not available either commercially or via another&#xD;
      mechanism. All enrolled subjects will receive the planned marketed dose of berotralstat, 150&#xD;
      mg QD. The study will assess the long term safety and tolerability of berotralstat.&#xD;
&#xD;
      Eligible subjects will be enrolled directly into Study BCX7353-312 (Study 312) from Studies&#xD;
      302 and 204. Subjects will receive berotralstat 150 mg administered orally once daily (QD).&#xD;
      Subjects will return to the clinic every 24 weeks for drug dispensation and safety monitoring&#xD;
      for up to 240 weeks (approximately 5 years).&#xD;
&#xD;
      Safety and tolerability will be evaluated through assessment of serious adverse events (SAEs)&#xD;
      and treatment-related, treatment-emergent adverse events (TEAEs). Up to 110 subjects are&#xD;
      planned to enroll.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label berotralstat (BCX7353) 150 mg orally administered QD.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking as this is open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number and proportion of subjects with a treatment-related TEAE</measure>
    <time_frame>240 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and proportion of subjects who experience a serious adverse event (SAE)</measure>
    <time_frame>240 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and proportion of subjects who experience a treatment-related Grade 3 or 4 TEAE</measure>
    <time_frame>240 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and proportion of subjects who experience a treatment-related Grade 3 or 4 treatment-emergent chemistry abnormality</measure>
    <time_frame>240 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and proportion of subjects who discontinue due to a TEAE</measure>
    <time_frame>240 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Hereditary Angioedema</condition>
  <condition>HAE</condition>
  <arm_group>
    <arm_group_label>BCX7353 Capsules 150 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Berotralstat (BCX7353) 150 mg capsule orally administered once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>berotralstat</intervention_name>
    <description>BCX7353 capsules administered orally once daily</description>
    <arm_group_label>BCX7353 Capsules 150 mg once daily</arm_group_label>
    <other_name>Orladeyo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males and females currently enrolled in BioCryst-sponsored Study 302 or 204&#xD;
&#xD;
          -  Able to provide written informed consent.&#xD;
&#xD;
          -  Would benefit from continued berotralstat treatment&#xD;
&#xD;
          -  Acceptable effective contraception&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Any condition or situation, including medical history that, in the opinion of the&#xD;
             investigator or sponsor, would interfere with the subject's safety or ability to&#xD;
             participate in the study&#xD;
&#xD;
          -  Use of other medications for long-term prophylaxis of HAE attacks at the Baseline&#xD;
             visit or any time during the study.&#xD;
&#xD;
          -  Use of any other investigational medicinal product at the Baseline visit or any time&#xD;
             during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vesna Grivcheva-Panoska, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PHI University Clinic of Dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>9198591302</phone>
    <email>clinicaltrials@biocryst.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Berotralstat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

